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Abstract
Background: Correct handling and storage of blood 
samples for coagulation tests are important to assure 
correct diagnosis and monitoring. The aim of this study 
was to assess the pre-analytical practices for routine coag-
ulation testing in European laboratories.
Methods: In 2013–2014, European laboratories were invited 
to fill in a questionnaire addressing pre-analytical require-
ments regarding tube fill volume, citrate concentration, 
sample stability, centrifugation and storage conditions for 
routine coagulation testing (activated partial thromboplas-
tin time [APTT], prothrombin time in seconds [PT-sec] and 
as international normalised ratio [PT-INR] and fibrinogen).
Results: A total of 662 laboratories from 28 different 
countries responded. The recommended 3.2% (105–
109 mmol/L) citrate tubes are used by 74% of the labora-
tories. Tube fill volumes ≥90% were required by 73%–76% 
of the laboratories, depending upon the coagulation test 
and tube size. The variation in centrifugation force and 
duration was large (median 2500 g [10- and 90-percentiles 
1500 and 4000] and 10 min [5 and 15], respectively). Large 
variations were also seen in the accepted storage time 
for different tests and sample materials, for example, for 
citrated blood at room temperature the accepted storage 
time ranged from 0.5–72 h and 0.5–189 h for PT-INR and 
fibrinogen, respectively. If the storage time or the tube 
fill requirements are not fulfilled, 72% and 84% of the 
respondents, respectively, would reject the samples.
Conclusions: There was a large variation in  pre-analytical 
practices for routine coagulation testing in European 
laboratories, especially for centrifugation conditions and 
storage time requirements.
Keywords: activated partial thromboplastin time; coagula-
tion tests; fibrinogen; haemostasis; pre-analytical phase; 
prothrombin time.
Introduction
Correct handling and storage of blood samples for coagu-
lation tests are important to assure a correct diagnosis of 
bleeding and thrombotic disorders as well as anticoagu-
lant monitoring [1, 2]. Incorrect handling of samples may 
lead to erroneous results which could jeopardise patient 
safety [1, 3]. In the case of traumatic blood sampling or 
vigorous or insufficient mixing of the sample, coagulation 
factors could be pre-activated. In the case of insufficient 
mixing a clot could be formed in the sample [3]. Under-
filled tubes or prolonged storage before testing may lead 
to a decrease of coagulation factor activities or altered 
impression of the anticoagulant effect in a monitoring 
situation [4–7]. In these circumstances, results would 
represent the situation in vitro and not in vivo. Because of 
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the risk of erroneous results of coagulation tests caused 
by handling in the pre-analytical phase, a harmonisation 
of the different pre-analytical practices is important [3, 8].
The most extensive international guideline for pre-
analytical handling of coagulation tests is the Clinical 
and Laboratory Standards Institute (CLSI) H21-A5 [7]. 
However, there are several other less extensive guidelines 
and reviews [1–3, 8–14] dealing with pre-analytical pro-
cedures in the coagulation field. It is uncertain to what 
extent laboratories use published guidelines, studies or 
reviews, or if they use their own studies or expert opinions 
for pre-analytical requirements. The CLSI guideline takes 
a conservative approach regarding pre-analytical han-
dling of samples for coagulation testing and states that, if 
less strict requirements are considered, laboratories must 
perform their own studies to show that their requirements 
are acceptable [7].
To the best of our knowledge, there is no published 
information on pre-analytical practices of routine coagu-
lation tests in laboratories from several European coun-
tries. The aim of this study was therefore to assess the 
actual pre-analytical practices for routine coagulation 
testing in European laboratories.
Materials and methods
This study was performed by the Haemostasis Working Group within 
the European Organisation for External Quality Assurance Providers 
in Laboratory Medicine (EQALM). A questionnaire on pre-analytical 
practices for routine coagulation testing was offered to European 
medical laboratories from their national external quality assurance 
(EQA) organiser through EQALM [15]. Each EQA organiser distributed 
the questionnaire either by email or via a web-link at the website of 
the EQA provider. The link to the study questionnaire was open from 
the autumn of 2013 to the spring of 2014. As the questionnaire was 
offered through the web in some countries, it was not possible to 
calculate the response rate in each country, as the total number of 
invited laboratories is unknown.
The questionnaire dealt with the most frequently used rou-
tine coagulation tests; i.e. activated partial thromboplastin time 
(APTT), prothrombin time in seconds (PT-sec) and as the interna-
tional normalised ratio (PT-INR) and fibrinogen. The following top-
ics were included in the questionnaire with a total of 29 questions: 
type of laboratory; type of coagulation tests performed; if external 
samples are received in the laboratory and how laboratories control 
that received samples are citrated plasma; citrate concentration of 
the tubes used; requirements for tube fill volume; centrifugation 
conditions; acceptable storage time (stability) for citrated blood 
in the primary tube before centrifugation, and after centrifugation 
(plasma on cells) and for aliquoted citrated plasma (fresh plasma 
transferred to a secondary tube), both at room temperature and 
refrigerated; and if a system for temperature control is applied dur-
ing storage and transport. Laboratories were also asked to mention 
the action they take if their requirements are not fulfilled, which 
source of guidance they use for tube fill and stability requirements 
and if they have national guidelines available (see questionnaire in 
the Supplementary material). Ethical approval was not necessary 
for this study.
Statistics
Descriptive statistics with median, 10- and 90-percentiles were used 
to describe the requirements and practices in the laboratories. Per-
centages were calculated based upon the number of laboratories 
responding to each question (missing responses excluded). The 
number of missing responses is only reported for questions where 
the response rate was less than 85%. SPSS version 22.0 (SPSS Inc.) 
was used for statistics and figures.
Results
In total, 662 laboratories from 28 different countries com-
pleted the questionnaire (Figure 1). The response rate 
to each question was generally above 85%. Sixty-seven 
percent of responding laboratories were public hospital 
laboratories, 19% were private outpatient laboratories, 7% 
private hospital laboratories, 3% public outpatient labo-
ratories and 4% other types. Half of the responding labo-
ratories (55%) perform only routine coagulation testing 
(one or more of the following tests: APTT, PT-sec, PT-INR 
and/or fibrinogen), while the remaining laboratories also 
perform more specialised coagulation tests (e.g. coagu-















































Figure 1: The number of responding laboratories from each of the 
participating countries.
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Samples received from outside the hospital 
and verification of citrated plasma
Sixty-six percent of the responding laboratories receive 
samples from outside the hospital. Of them, 62% 
receive only citrated whole blood, whereas the others 
receive  whole blood and aliquoted plasma or only 
 aliquoted plasma. Of the laboratories receiving aliquoted 
plasma, 36% do not routinely check if the received sample 
material is citrated plasma (and not, e.g. serum, EDTA 
or heparin plasma), 29% only check in the case of unex-
pected results, and 34% always check. Of the laboratories 
performing a check, 50% check that “citrated plasma” is 
written on the tube label and 50% perform one or more 
laboratory tests. Of the latter, only 50% (n = 26) specified in 
this survey which laboratory test(s) they perform. Fibrino-
gen measurement is performed by 20 laboratories, while 
some perform either an electrophoresis or measure one or 
more coagulation screening tests (APTT, PT-sec, thrombin 
time) or electrolytes (calcium, sodium, potassium and/or 
magnesium). Two laboratories require the primary citrate 
tube to be attached to the aliquoted sample (e.g. with an 
elastic band).
Citrate concentration and tube fill 
requirements
The majority of respondents (74%) use tubes with a citrate 
concentration of 3.2% (105 or 109 mmol/L), 12% use tubes 
with a citrate concentration of 3.8% (129 mmol/L) and 14% 
use both.
Depending upon the routine coagulation test in 
question, 73%–76% only accept tube fill volumes of 
≥90% for both regular and paediatric (low volume) 
tubes, while 15%–17% accept fill volume of ≥80% and 
5%–8% fill volumes of ≥70%. Only 1%–4% answered 
specifically that they do not have tube filling require-
ments or that they accept tube fill volumes of less than 
70% (Figure 2). The question regarding tube fill volume 
was not answered by 4%–15% for the different routine 
coagulation tests for regular tubes, and by 41%–46% for 
paediatric tubes. When underfilled tubes are received 
by laboratories, 84% would reject the sample and ask 
for a replacement (Figure 3). Forty-four percent stated 
own experience, while 56% stated at least one guide-
line as their source of requirements for tube fill volume. 
Of those using guidelines, only 28% stated a guideline 
also mentioned by others (Table 1) and 67% did not 
state any name.
Centrifugation conditions
The median (10- and 90-percentiles) centrifugation force 
was 2500 g (1500 and 4000), the centrifugation duration 
was 10 min (5 and 15) and the median centrifugation tem-
perature was 20 °C (18 and 24). The variation of combi-
nations of centrifugation force and duration was large 
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Figure 2: Percentage of laboratories (y-axis) accepting the different 
tube fill volumes (x-axis) in regular and low volume/pediatric tubes 
for different routine coagulation tests.
APTT, activated partial thromboplastin time; PT-sec, prothrombin 






































Figure 3: The percentage of responding laboratories (y-axis) 
performing different actions (x-axis) if a sample does not fulfill tube 
fill volume requirements (white bars) or stability requirements (grey 
bars).
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(Figure 4). When only laboratories using two centrifuges 
were included (n = 110 [17%]), the median centrifugation 
force was 2200 g (1500 and 3000) and the duration was 
10 min (7 and 15) for the centrifuge with the lowest cen-
trifugation force while it was 3200 g (2000 and 4500) and 
5 min (3 and 15) for the centrifuge with the highest cen-
trifugation force. More than 95% of the laboratories centri-
fuged their samples at room temperature (18–24 °C).
Sample stability and storage
Large variation in the accepted storage time of the samples 
was found between laboratories for all coagulation tests 
studied, for all sample materials and for both room tem-
perature and refrigerator storage (Figure 5). Median sta-
bilities given for the different routine coagulation tests 
in the different sample materials and temperatures were 
rather similar, but a wider range was seen for PT-INR and 
fibrinogen compared to APTT (Figure 5 and Table 2).
Fewer laboratories have storage time requirements 
for refrigerated samples compared to samples stored at 
room temperature, and 32%, 35%, 30% state not to accept 
refrigerated citrated whole blood for APTT, PT-INR and 
fibrinogen, respectively (Table 2). Fewer laboratories 
have specific requirements for APTT in patients treated 
with unfractionated heparin (APTT UH) and for PT-INR 
in patients treated with vitamin K antagonists (INR VKA) 









































Figure 4: The combination of centrifugation force (g) (x-axis) and 
duration (minutes) (y-axis) for all the centrifuge conditions given 






























































































Figure 5: Stability requirements (y-axis) at room temperature (A) 
and in refrigerator (B) given by the responding laboratories for 
the different routine coagulation tests (x-axis) in different sample 
materials (citrated whole blood, citrated plasma on cells and 
citrated aliquoted plasma).
The tables below the Figure panels show the number of laboratories 
stating stability requirements of more than 72 h for the given 
condition and analyte. The boxes in the figure represent the median 
(horizontal black line) and the 25- and 75-percentiles (lower- and 
upper border, respectively). The range is depicted by the vertical 
lines from the boxes, the circles are outliers, while the asterix’ are 
extreme outliers (SPSS version 22.0 [SPSS Inc.]). APTT, activated 
partial thromboplastin time; UH, unfractionated heparin; PT-INR, 
prothrombin time international normalised ratio; VKA, vitamin K 
antagonists. *Stability requirements for PT-INR and PT-sec were 
merged in the same question.
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If samples are received after the maximum storage 
time, 72% would reject the sample and ask for a replace-
ment (Figure 3). More than half of the laboratories (61%) 
use at least one guideline for acceptable storage time, 
while 39% stated that the requirements were based on own 
experience or other studies. Of those stating to use at least 
one guideline, only 28% stated a guideline also mentioned 
by others (Table 1), and 64% did not state any name.
In more than half of the laboratories (56%), the 
samples are routinely stored in primary tubes (plasma on 
cells after centrifugation) for potential extra requests. Of 
these laboratories, 79% store the samples capped, 12% 
covered (e.g. with a plastic film or cardboard) and 9% 
uncapped and uncovered. Half of the laboratories (51%) 
usually store the samples at room temperature, 25% in a 
refrigerator, while 9% and 3% store the samples at −20 and 
−80 °C, respectively (12% did not answer this question).
In general, 72%, 96% and 95% of the laboratories 
have a system for temperature control at room tempera-
ture, in refrigerators and freezers, respectively. Only 42% 
have a system for temperature control during transport 
(24% did not answer).
Availability of national guidelines on  
pre-analytical issues in coagulation testing
Among the laboratories, 63% answered “yes” we have a 
national guideline. Of these, 58% stated to have a guide-
line from a national society, 8% from a government or 
national health care service, 26% from experts in the field 
and 8% from “others”. Only 45% specified the name of 
the guideline or the source of their recommendations. Of 
the French laboratories, 73% specified a guideline from 
Groupe d’Etude sur l’Hémostase et la Thrombose (GEHT) 
[9], also stated by 3% of the Belgian laboratories. Of the 
Dutch laboratories, 53% stated a guideline from Stichting 
Kwaliteitsbewaking Medische Laboratoriumdiagnostiek 
(SKML) (Dutch EQA organisation) [10], also stated by 1.5% 
of the Belgian laboratories. Of the laboratories in the UK 
and Ireland, 15% and 8%, respectively, stated the name of 
a guideline from the British Society for Haematology (BSH) 
[11]. Overall, 19 and three laboratories stated the name of 
the international guidelines from CLSI (H21-A5) [7] and the 
World Health Organization (WHO) [12], respectively.
Discussion
The main findings of this study were that the  pre-analytical 
practices for routine coagulation testing in European 
laboratories varied widely, especially regarding centrifu-
gation conditions and sample storage time requirements. 
In addition, few countries have national guidelines for 
pre-analytical issues in haemostasis testing acknowl-
edged by a considerable number of the responding labo-
ratories in the country.
Samples received from outside the hospital 
and citrate plasma verification
Performing coagulation testing in the wrong sample type 
(EDTA or heparin plasma or serum) could lead to erro-
neous results that could jeopardise patient safety [2]. 
However, it is challenging for laboratories who receive 
aliquoted plasma (secondary tubes) to verify that the 
correct sample material is received. Most laboratories in 
this study check that citrated plasma is written on the 
secondary tube and a few state that the primary tube 
should be sent together with the secondary tube (rec-
ommended in a very recent guidance [14]), but this is 
no guarantee. A few laboratories measure electrolytes, 
which may be helpful to distinguish EDTA plasma from 
citrated plasma and serum/lithium heparin plasma if 
used according to a specific algorithm [16]. However, this 
is resource demanding and is probably only performed 
if the wrong sample material is suspected. Fibrinogen 
measurement, mentioned by some laboratories, may 
indicate that the sample material is serum (no fibrino-
gen). Electrophoresis, mentioned by others, is a more 
resource-demanding fibrinogen method (no fibrinogen 
band in serum). Extremely prolonged or unmeasur-
able APTT, PT-sec and PT-INR are measured in sodium 
heparin plasma or serum [3] but could also be caused 
by supra-therapeutic concentrations of heparin/heparin 
contamination from a catheter. Measuring APTT, PT-sec, 
PT-INR and fibrinogen in EDTA plasma may apparently 
give reasonable results (normal or slightly pathological) 
and it is therefore more difficult to suspect wrong sample 
material [3]. Consequences may be erroneous dosing 
with unfractionated heparin (APTT) or vitamin K antago-
nists (PT-INR), or if further testing is performed, e.g. false 
diagnosis of factor VIII deficiency [3]. Unfortunately, an 
easily accessible and effective way to guarantee citrated 
plasma is to the best of our knowledge not available. 
It is preferable for the laboratories to receive primary 
tubes because this would ensure correct sample mate-
rial and the opportunity to check the tube fill volume [5]. 
However, this requires that the samples are stable during 
transport.
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Citrate concentration and tube fill 
requirements
The majority of the European laboratories use 105 or 
109 mmol/L (3.2%) sodium citrate tubes, as recommended 
by most guidelines (Table 1). It was found that the interna-
tional sensitivity index (ISI) was approximately 10% lower 
when determined in 129 mmol/L (3.8%) compared to 3.2% 
tubes, resulting in higher PT-INR results in 3.8% tubes, 
especially for the most sensitive thromboplastin reagents 
[17] in warfarin users [18]. In addition, the results from 
3.8% tubes are more prone to be affected by underfilling, 
also potentially resulting in prolonged clotting times (e.g. 
APTT, PT-sec, PT-INR) [4].
In general, clotting times increase with decreasing 
tube fill volumes, which is caused by increased plasma 
dilution (liquid citrate in the tube) and increased 
calcium binding citrate per volume blood [4, 19, 20]. Most 
responding laboratories require the sample tubes to be 
almost completely filled (≥90%), which is also recom-
mended by the CLSI guideline [7]. It is, however, shown 
that the results were not statistically significantly dif-
ferent when obtained in 3.2% 4.5–5.0 mL citrate tubes 
with 60%, 70% and 60% tube fill volume, for PT-sec, 
APTT and fibrinogen, respectively [4, 19, 20]. In 3.6 mL 
tubes (3.2%), the acceptable fill volume was found to 
be 67%, 89% and 78% for PT-sec, APTT and fibrinogen, 
respectively [8], and in 2.7 mL (3.2%) tubes, it was 70%, 
90% and 80% [21]. It should be noted that the accept-
ance criteria in these studies are different or not given. 
Paediatric tubes (small volume tubes [≤2.5 mL]) seem to 
be more prone to underfilling than regular tubes [22], 
still fewer responding laboratories had tube fill require-
ments for these tubes. In general, the tubes should be 
completely filled, however, the consequences of under-
filling should be studied to be able to give advice to 
clinicians in emergency situations where underfilled 
tubes are received. Laboratories using different tubes 
(manufacturer and/or volume) than tested in published 
studies should validate their own system for acceptable 
tube fill volume.
Centrifugation conditions
Centrifugation forces and durations stated by laborato-
ries varied widely and may be reflected by the fact that 
different guidelines give different recommendations 
(Table 1). Short centrifugation times may give increased 
coagulation times in routine coagulation tests if low 
centrifugation forces are used, i.e. 1500 g for less than 
2 min prolong APTT and less than 5 min reduce fibrino-
gen concentration (Clauss method) [23]. Other studies 
have shown that high speed centrifuges (>4000 g) can be 
combined with short centrifugation times (2–5  min) for 
PT-sec, PT-INR, APTT and fibrinogen [24–26], and these 
centrifuges are used to some extent by the laboratories 
(Figure 4). Criteria for acceptable changes differ in the 
different studies; most of the studies only evaluate the 
results when the samples were analyzed right after sam-
pling and centrifugation and some only have samples 
with results within the reference interval. Studies com-
paring different centrifugation conditions and their effect 
on the routine coagulation results are highly warranted. 
The CLSI guideline states that plasma should be platelet 
poor (thrombocytes <10 × 109/L) and that centrifugation 
procedure should be validated every 6  months or after 
modification of the centrifuge to ensure the thrombocyte 
count does not exceed this limit [7]. However, the CLSI 
guideline does not state any acceptance criteria regarding 
the size of acceptable changes in coagulation test results. 
The need for harmonising centrifugation conditions in 
coagulation is increasing due to time efficiency problems 
of full automation laboratory systems when coagulom-
eters are included.
Sample stability and storage
The acceptable storage time varies widely amongst Euro-
pean laboratories, especially for PT-INR and fibrinogen 
(in all sample materials). The CLSI guideline is very strict, 
demanding all coagulation tests to be centrifuged and 
analyzed within 4 h, except PT-INR within 24 h and APTT 
with unfractionated heparin treatment within 2  h, but 
also states that longer storage time could be used if this 
is validated in one’s own laboratory [7]. There are studies 
indicating that both PT-INR and fibrinogen are stable for 
48 h and APTT for 24 h, both in citrated blood and plasma 
[5, 6]. PT-INR and fibrinogen have even been shown to be 
stable for up to 72 h [27] and 7 days [28], respectively. The 
explanation for the longer acceptable storage times found 
in some published studies could be less strict acceptance 
criteria. The large variation in the guidelines (Table 1), and 
thereby the large variation in requirements in the labora-
tories, could be explained by this. It could also be that the 
laboratories have performed their own studies. Some pub-
lished studies have used a mean difference of the results 
of 10% as a criterion for stability [5, 6], while others use 
more strict criteria, such as desirable bias based upon 
biological variation (APTT ± 2.8%, PT-sec ± 2%, fibrino-
gen ± 4.8%) [29].
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The wide range in storage time requirements for 
PT-INR could in part be explained by the Nordic coun-
tries accepting longer storage time for PT-INR (median 
24–48 h for the different sample materials) compared to 
the other countries (4–8 h). A similar tendency could be 
seen for fibrinogen, while accepted storage times for APTT 
were rather similar (data not shown). The longer storage 
time for PT-INR in the Nordic countries could be due to 
the use of the Owren method in these countries, not being 
affected by the fast decrease of the labile factor V [6], but 
this cannot explain the longer storage times accepted for 
fibrinogen.
Citrated blood for coagulation testing should not be 
stored in a cold environment because of possible cold acti-
vation of factor VII and thereby shorter coagulation times 
[30] and also loss of the von Willebrand factor and factor 
VIII [31, 32]. This is in agreement with the fact that many 
laboratories in the present study do not have requirements 
for acceptable storage times of refrigerated citrated blood 
samples (Table 2).
Most laboratories have a system for temperature 
control for sample storage in the laboratory, but not 
during transportation of samples. To avoid that samples 
are affected by low (cold activation during winter) or 
high temperatures, one could demand transportation of 
samples in specific boxes made for avoiding extremes of 
temperatures.
Although use of automated instruments with cap-
piercing probably is increasing, 20% of the laborato-
ries still store the samples uncapped for potential later 
requests. Prolonged storage of uncapped samples may 
lead to pH changes in the samples and thereby an increas-
ing risk of erroneous results (prolonged clotting times 
with a pH decrease) [3, 33].
Clinical consequences of pre-analytical 
errors
Standardisation of the pre-analytical phase is impor-
tant to avoid erroneous results released to the clinicians 
leading to wrong diagnoses and treatment. However, it 
is also important that the laboratory understands the 
effect of different pre-analytical errors, to help clinicians 
interpret a result from a non-optimal sample in case of an 
emergency. In the present study, as many as 84% and 72% 
of the responding laboratories would reject the samples if 
the requirements for tube fill volume and stability, respec-
tively, were not fulfilled. In these cases, it is known that 
the clotting times will be falsely prolonged [4, 19, 34], and 
a result within the reference interval would potentially be 
helpful for the clinician to avoid delay in diagnosis and 
treatment. However, it is important to analyse an opti-
mally drawn blood sample as soon as possible to confirm 
the results. In other instances, the effect of the pre-analyti-
cal error is unpredictable, especially if several errors occur 
at the same time. In general, strict rules for pre-analytical 
handling of blood samples should be followed, but the 
laboratory should be able to give advice to clinicians if a 
pre-analytical error is known.
Pre-analytical guidelines
Some countries have national guidelines for pre-analyti-
cal issues (Table 1), but only France and the Netherlands 
have national guidelines (GHET [9] and SKML [10], respec-
tively) which are widely known by the responding labo-
ratories. The BSH guideline [11], was mentioned by a few, 
but it does not deal in detail with all the issues included 
in the present questionnaire. This could also be the reason 
why some reported the international guidelines from CLSI 
[7] and WHO [12] as their “national” guidelines.
The guidelines differ in some of their recommenda-
tions (Table 1) and none of them have discussed criteria 
for acceptable changes. The CLSI guideline is from 2008 
and the WHO from 2002, so the several published studies 
in recent years should encourage a revised version of 
these guidelines including criteria used for deciding on 
acceptable pre-analytical handling.
Conclusions
Large variations in pre-analytical practices for routine 
coagulation testing were found in the European labora-
tories. This might be caused by the different recommen-
dations in guidelines and results from published or own 
studies. Criteria for clinically acceptable changes are not 
included in the guidelines. The clinical consequences of 
the large variation in pre-analytical requirements are not 
known.
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